Comparing two surgical methods for small lung tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the effectiveness of lobectomy versus segmentectomy in patients with lung adenocarcinoma measuring 2 cm or less, particularly focusing on those with micropapillary and solid subtypes identified through intraoperative frozen sections. The study aims to determine which surgical approach leads to better recurrence-free survival and overall survival rates. By utilizing advanced intraoperative techniques, the research seeks to provide clearer guidance on surgical strategies for small lung tumors. It is a multi-center study conducted at Shanghai Pulmonary Hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Tumor size ≤ 2 cm;
* Solitary tumor and located in the outer third of the lung field;
* Preoperative CT indicated that the nodules were single nodules or Concomitant nodules was less than minimal invasive adenocarcinoma;
* Intraoperative frozen section confirmed invasive lung adenocarcinoma and with micropapillary and solid patterns positive (\>5%);
* Confirmation of R0 status by intraoperative frozen section analysis;
* Pulmonary function could withstand both segmentectomy and lobectomy (FEV1 \> 1.5 L or FEV1% ≥ 60%);
* Sufficient organ function;
* Performance status of 0,1 or 2；
* Written informed consent.

Exclusion Criteria:

* The tumor is close to the hilum, which cannot perform segmentectomy ;
* Patients suspected of lymph node positive by preoperative examination, including CT scans and mediastinal lymph node biopsy;
* Evidence revealed locally advanced or metastatic disease;
* Intraoperative exploration revealed accidental pleural dissemination.
* Patients with severe damage to heart, liver and kidney function (grade 3 \~ 4, Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) over 3 times the normal upper limit, Cr over the normal upper limit).
* Patients concomitant with other malignant tumors；
* Patients had prior chemotherapy, radiotherapy or molecular targeted therapy for this malignancy.
* History of severe heart disease, heart failure, myocardial infarction within the past 6 months.
* The patients who were not suitable for inclusion by researchers' evaluation.

Where it's running

• Shanghai Pulmonary Hospital
  Yangpu, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Long Xu, MD
• Email: xulong1228@163.com
• Phone: 15801783037

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DBC-664 in adults with solid tumors

  A first-in-human study will test DBC-664 to see if it is safe and tolerable in adults with various advanced solid tumors and may hint at anti-tumor activity.

  Recruiting at 7 sites Phase 1 TCG Labs Soleil · Denver, Colorado and 6 other locations · NCT07705035

• Ex Vivo Drug Response Testing in Lung Adenocarcinoma with Malignant Pleural Effusions

  This study tests whether the way cancer cells from pleural effusions respond to drugs outside the body can predict how patients will respond to treatment.

  Recruiting Sheba Medical Center · Ramat Gan, Israel · NCT07636252

• Vortioxetine for cognitive problems in ALK/ROS1-positive NSCLC treated with lorlatinib

  This observational study tests whether vortioxetine can help with cognitive and neurological side effects in adults with ALK/ROS1-positive NSCLC who are taking lorlatinib.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá · NCT07633626

• Targeted FSRT plus bevacizumab versus hippocampus-sparing whole-brain radiation for people with lung adenocarcinoma that has spread to the brain

  This will test whether focused 5-day fractionated stereotactic radiotherapy (FSRT) combined with bevacizumab works better than hippocampus-avoidant whole-brain radiotherapy with a simultaneous boost at controlling brain metastases and protecting memory in adults with lung adenocarcinoma and extensive brain metastases.

  Recruiting at 3 sites Phase 3 Sun Yat-sen University · Chongqing, Chongqing Municipality and 2 other locations · NCT07481786

• 7-day low-carb, high-fat (ketogenic) diet to improve FDG PET/CT detection of lepidic lung adenocarcinoma

  This trial will test whether a personalized 7-day ketogenic (low-carb, high-fat) diet before an FDG PET/CT can improve detection of lepidic-predominant lung adenocarcinoma in adults with a suspicious lung nodule or confirmed diagnosis.

  Recruiting Fondazione del Piemonte per l'Oncologia · Candiolo, Torino (TO) · NCT07479095

• Partial high-dose tumor irradiation combined with immunotherapy for unresectable lung adenocarcinoma

  This trial will try giving very high-dose radiation to the central part of large, unresectable lung adenocarcinomas while preserving the surrounding immune tissue and pairing that with an immune checkpoint drug for patients who have no remaining standard treatment options.

  Recruiting Karl Landsteiner University of Health Sciences · Krems, Austria · NCT07423169

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.